Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A

Wattana Mahattanakul, Thomas O. Crawford, John W. Griffin, Jonathan M. Goldstein, David R. Cornblath

Research output: Contribution to journalArticlepeer-review


Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated polyneuropathy for which there are effective therapies. However, not all patients improve with these treatments. Eight patients with CIDP, two with IgG monoclonal gammopathies, were treated with cyclosporin-A (3 to 5 mg/kg/day). In three, this treatment was successful. It was unsuccessful in four patients who were resistant to other treatments and in one who had initially received cyclosporin-A. There were no serious side effects. In selected patients with CIDP, cyclosporin-A is a potentially useful treatment.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalJournal of Neurology Neurosurgery and Psychiatry
Issue number2
StatePublished - Feb 1996


  • Cyclosporin-A
  • Inflammatory demyelinating polyneuropathy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A'. Together they form a unique fingerprint.

Cite this